Redeye: Surgical Science Sweden Q4 2023 - Long-term high quality, short-term black box
Redeye updates its estimates following Surgical Science’s Q4 2023 report, which featured an unusually soft end to the year that we failed to anticipate. We believe the company’s long-term equity story remains unchanged, though 2023 showed how the market has difficulty pricing the considerable sequential volatility of the company’s sales.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/